Spectrum Pharmaceuticals, Inc. (NASDAQ-GS: SPPI) is a biotechnology company engaged in acquiring, developing and commercializing drug products, with its chief focus on oncology and hematology. The company currently markets two oncology drugs: FUSILEV for Injection in the United States, and ZEVALIN Injection, for which the company has global marketing rights. Spectrum, which has a growing pipeline of product candidates in advanced-stage Phase 2 and Phase 3 studies, recently celebrated 10 years in business. For more information, visit the company’s Web site at www.sppirx.com.

Rodman & Renshaw is a full-service investment bank dedicated to providing corporate finance, strategic advisory, and related services to public and private companies across multiple sectors and regions. Rodman also provides research, sales, and trading services. According to Sagient Research Systems, Rodman has been ranked the #1 Placement Agent in terms of the aggregate number of PIPE and RD financing transactions completed every year since 2005. For more information on Rodman & Renshaw, visit www.rodmanandrenshaw.com.

Let us hear your thoughts below: